Skip to main content Help with accessibility Skip to main navigation

Ulipristal acetate

Indication

Intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women who have not reached menopause when uterine fibroid embolisation and/or surgical treatment options are not suitable or have failed.

MHRA Aug 2018 Update - Ulipristal

Drug Safety Update March 2020 - Esmya (ulipristal acetate): suspension of the licence due to risk of serious liver injury

Black

Brand:

Esmya

Nice TA:

Commissioning responsibility:

CCG

PbR excluded:

No

BNF chapter:
Genito-urinary system

Background

Recommendation

LSCMMG Recommendation:

Black

Reason for decision:

Not recommended for prescribing on the NHS in Lancashire & South Cumbria

Supporting documents:

Decisions of Lancashire local decision making groups

Pending
Pending
Pending
Pending
Pending
Pending
Pending
Pending
What do the colours mean?

Last Updated: 01 - Sep - 2018